BiotechTube

troriluzole + Placebo

Phase 3Active
1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinocerebellar Ataxias

Conditions

Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10

Trial Timeline

Mar 8, 2019 → Jun 1, 2026

NCT ID
NCT03701399

About troriluzole + Placebo

troriluzole + Placebo is a phase 3 stage product being developed by Biohaven for Spinocerebellar Ataxias. The current trial status is active. This product is registered under clinical trial identifier NCT03701399. Target conditions include Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2.

What happened to similar drugs?

0 of 6 similar drugs in Spinocerebellar Ataxias were approved

Approved (0) Terminated (0) Active (6)
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low dose + PlaceboKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
🔄KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
🔄KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
🔄KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04693351Phase 3Completed
NCT04641143Phase 3Completed
NCT03701399Phase 3Active
NCT03829241Phase 3Completed
NCT03299166Phase 2/3Completed

Competing Products

15 competing products in Spinocerebellar Ataxias

See all competitors
ProductCompanyStageHype Score
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
KPS-0373, High dose + KPS-0373, Low dose + PlaceboKissei PharmaceuticalPhase 3
40
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
47
KPS-0373 + PlaceboKissei PharmaceuticalPhase 2
35
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
40
KPS-0373Kissei PharmaceuticalPhase 2
35
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
40
varenicline + placeboPfizerPhase 2
35
BIIB132 + BIIB132-Matching PlaceboBiogenPhase 1
18
IVIGBaxterPhase 2
32
Intravenous Immune Globulin (IVIG)BaxterPhase 1
22
ARO-ATXN2 Injection + PlaceboArrowhead PharmaceuticalsPhase 1
33
Troriluzole + Placebo + TroriluzoleBiohavenPhase 2/3
32
BHV-4157BiohavenPre-clinical
24